Terence Hall

803 total citations
16 papers, 521 citations indexed

About

Terence Hall is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Terence Hall has authored 16 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Terence Hall's work include Fibroblast Growth Factor Research (7 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Advanced Breast Cancer Therapies (3 papers). Terence Hall is often cited by papers focused on Fibroblast Growth Factor Research (7 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Advanced Breast Cancer Therapies (3 papers). Terence Hall collaborates with scholars based in United States, Italy and Czechia. Terence Hall's co-authors include Brian Schwartz, Giovanni Abbadessa, Sudharshan Eathiraj, Ronald E. Savage, Julia Kazakin, Kyriakos P. Papadopoulos, Michael J. Wick, Bassel F. El‐Rayes, Nicola Personeni and Nevena Damjanov and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Terence Hall

14 papers receiving 512 citations

Peers

Countries citing papers authored by Terence Hall

Since Specialization

Citations

This map shows the geographic impact of Terence Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence Hall more than expected).

Fields of papers citing papers by Terence Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence Hall. The network helps show where Terence Hall may publish in the future.

Co-authorship network of co-authors of Terence Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Terence Hall. A scholar is included among the top collaborators of Terence Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terence Hall. Terence Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia 2025 ·Blood Advances ·Farhad Ravandi, Sravanti Rangaraju, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Musa Yılmaz, (unknown), Terence Hall, John D. Grabenstein, (unknown), (unknown), William C. Zamboni, Erica D. Warlick, Michael J. Kelly, David A. Roth, Gabriel Ghiaur	1
2	Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC). 2023 ·Journal of Clinical Oncology ·Dejan Juric, Debra L. Richardson, Babar Bashir, Manish Sharma, Kyriakos P. Papadopoulos, (unknown), Graeme Hodgson, (unknown), Sofia Paul, Terence Hall, David A. Roth, Michael T. Kelly, (unknown), Virginia M. Klimek	2
3	Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel. 2023 ·Journal of Clinical Oncology ·Babar Bashir, Manish Sharma, Dejan Juric, Kyriakos P. Papadopoulos, Erika Hamilton, Debra L. Richardson, Geoffrey I. Shapiro, Vaibhav Sahai, Niharika B. Mettu, Zev A. Wainberg, Olatunji B. Alese, Tomislav Dragovich, Graeme Hodgson, (unknown), Terence Hall, Sofia Paul, David A. Roth, Michael T. Kelly, (unknown), Virginia M. Klimek	2
4	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 2018 ·British Journal of Cancer ·Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William Proctor Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh, Vittorina Zagonel, Kyriakos P. Papadopoulos, Terence Hall, Yunxia Wang, Brian Schwartz, Julia Kazakin, Sherrie Bhoori, Filippo de Braud, Walid L. Shaib	265
5	Abstract 4797: In vitro and in vivo effect of ARQ 531 on Trk family kinases 2018 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Sudharshan Eathiraj, Terence Hall, Brian Schwartz	0
6	Abstract 4808: Combinations of imatinib mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and preclinical models 2018 ·Cancer Research ·(unknown), (unknown), Karthik Devarajan, (unknown), (unknown), Jeffrey M. Farma, Nestor F. Esnaola, (unknown), Yi Yu, Brian Schwartz, Terence Hall, Margaret von Mehren, Lori Rink	1
7	Abstract LB-018: ARQ 531, a novel and reversible inhibitor of Bruton's tyrosine kinase, displays favorable oral bioavailability and exposure in patients with B-cell malignancies 2018 ·Cancer Research ·Terence Hall, Yi Yu, Sudharshan Eathiraj, Deborah M. Stephens, Ian W. Flinn, Jennifer A. Woyach, Brian Schwartz, Ronald E. Savage	1
8	In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor 2017 ·Anti-Cancer Drugs ·Yi Yu, Terence Hall, Sudharshan Eathiraj, Michael J. Wick, Brian Schwartz, Giovanni Abbadessa	21
9	ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3 2017 ·Bone ·Lukáš Bálek, Iva Gudernová, Iva Veselá, (unknown), (unknown), Michaela Kunova Bosakova, Miroslav Vařecha, Pavel Němec, Terence Hall, Giovanni Abbadessa, Nan Hatch, Marcela Buchtová, Pavel Krejčı́	15
10	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. 2017 ·Journal of Clinical Oncology ·Vincenzo Mazzaferro, Bassel F. El‐Rayes, Christian Cotsoglou, William Proctor Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi S. Braiteh, Vittorina Zagonel, Kyriakos P. Papadopoulos, Terence Hall, Yunxia Wang, Giovanni Abbadessa, Brian Schwartz, Julia Kazakin, Michele Droz Dit Busset, Walid L. Shaib	23
11	Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation 2016 ·PLoS ONE ·Terence Hall, (unknown), Sudharshan Eathiraj, Yunxia Wang, Ronald E. Savage, Jean‐Marc Lapierre, Brian Schwartz, Giovanni Abbadessa	76
12	Abstract 374: In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitor 2016 ·Cancer Research ·(unknown), Ronald E. Savage, Sudharshan Eathiraj, Terence Hall, Brian Schwartz, Giovanni Abbadessa	2
13	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 2015 ·PLoS ONE ·Yi Yu, Ronald E. Savage, Sudharshan Eathiraj, (unknown), Michael J. Wick, Terence Hall, Giovanni Abbadessa, Brian Schwartz	103
14	Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751 2015 ·Molecular Cancer Therapeutics ·Sudharshan Eathiraj, Brian Schwartz, (unknown), Michael J. Wick, Terence Hall, Fang Chai, Jasgit C. Sachdev, Giovanni Abbadessa	0
15	Abstract B151: In FGFR2 driven tumors, preclinical pharmacokinetics (PK), pharmacodynamics (PD) and efficacy translate into clinical activity of ARQ 087 2015 ·Molecular Cancer Therapeutics ·Terence Hall, Ronald E. Savage, Brian Schwartz, Yi Yu, Yunxia Wang, Julia Kazakin, Giovanni Abbadessa, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Walid L. Shaib, Bassel F. El‐Rayes	1
16	Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. 2015 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Anthony W. Tolcher, Amita Patnaik, Drew Rasco, (unknown), M. Beeram, Ronald E. Savage, Terence Hall, Brian Schwartz, Julia Kazakin, Patricia LoRusso	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact